Clinical Trials Logo

Periampullary Adenocarcinoma clinical trials

View clinical trials related to Periampullary Adenocarcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03724994 Recruiting - Pancreatic Cancer Clinical Trials

Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer

CHAMP
Start date: October 30, 2018
Phase:
Study type: Observational [Patient Registry]

The CHAMP (Chemotherapy, Host response And Molecular dynamics in Periampullary cancer) study is a prospective, single-arm observational study that started Sept 1 2018. Patients diagnosed with pancreatic or other periampullary adenocarcinoma undergoing adjuvant och palliative chemotherapy are invited to participate. The study will examine the tumors' molecular dynamics and how this may change over time and with treatment. Primary endpoint will be overall survival, secondary endpoints will be disease specific survival, time to progression, and quality of life. We estimate that 90 patients will be included in the study per year.

NCT ID: NCT02757859 Recruiting - Cholangiocarcinoma Clinical Trials

High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Start date: April 27, 2016
Phase: N/A
Study type: Interventional

This randomized clinical trial studies how well high volume washing of the abdomen works in increasing survival after surgery in patients with pancreatic cancer that can be removed by surgery. High volume washings may remove free floating cancers present after surgery and help prolong survival in patients with pancreatic cancer.

NCT ID: NCT01811277 Recruiting - Pancreatic Cancer Clinical Trials

SOX Sequential S-1 in Advanced Biliary Tract Carcinoma(BTC)and Pancreatic Cancer

Start date: July 2010
Phase: Phase 2
Study type: Interventional

This is an exploratory, single-armed, open label study on the efficacy and safety of sequential S-1 therapy after SOX in unresectable metastatic or locally advanced biliary system or periampullary cancer or pancreatic cancer patients. The primary endpoint is Objective response rate and secondary endpoint is progression free survival , overall survival ,1 year survival rate and safety.